Observation of CBD therapy inpatients with intractable epilepsy
Phase 2
Recruiting
- Conditions
- G40Epilepsy
- Registration Number
- DRKS00013177
- Lead Sponsor
- Abteilung für Epileptologie des Universitätsklinikums Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
pharmacoresistant epilepsy, treatment with at least one anticonvulsive drug, CBD therapy
Exclusion Criteria
cannabinoid treatment within 4 weeks of screening, pregnancy, instable hepatic or renal disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage change of seizure frequency per month of motor seizures after 3 months of CBD compared to 1 month of baseline
- Secondary Outcome Measures
Name Time Method Percentage change of seizure frequency per month of all seizures after 3 months of CBD compared to 1 month of baseline plus change of motor and all seizures per month after 6,12,18,24,36 months of treatment compared to baseline